CIK 0001359931
- Non-accelerated filer
- Smaller reporting company
Protara Therapeutics, Inc.
Sign in to watch- Ticker
- TARA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 204580525
- Phone
- +1 646-844-0337
- Business address
- 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK, NY, 10010
- Former names
- Protara Therapeutics, Inc., ArTara Therapeutics, Inc., PROTEON THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-15 | SARGEN GREGORY Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2025-06-12 | SARGEN GREGORY Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2024-06-07 | SARGEN GREGORY Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2023-06-07 | SARGEN GREGORY Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2022-06-08 | SARGEN GREGORY Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-09 | SARGEN GREGORY Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2020-06-09 | SARGEN GREGORY Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2020-01-10 | SARGEN GREGORY Director | Grant or award | +31,000 | 31,000 |
Page 1 of 1 · 8 trades